Skip to main content
NewsPublications

Scientific articles in 2019

By 31 December 2019January 26th, 2022No Comments

Scientific articles in 2019

In 2019, ADx NeuroSciences’ collaborators were intensively participating in groundbreaking scientific research resulting in many R&D studies and publications. An overview of all articles with ADx involvement, published in 2019, can be found below.

1. The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?

Fichou Y, Al-Hilaly YK, Devred F, Smet-Nocca C, Tsvetkov PO, Verelst J, Winderickx J, Geukens N, Vanmechelen E, Perrotin A, Serpell L, Hanseeuw BJ, Medina M, Buée L, Landrieu I.
Acta Neuropathol Commun. 2019 Mar 1;7(1):31. doi: 10.1186/s40478-019-0682-x.

2. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults.

Schaeverbeke J, Gille B, Adamczuk K, Vanderstichele H, Chassaing E, Bruffaerts R, Neyens V, Stoops E, Tournoy J, Vandenberghe R, Poesen K.
J Neurochem. 2019 Apr;149(1):139-157. doi: 10.1111/jnc.14680. Epub 2019 Mar 20.

3. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen EDe Vos A, Habert MO, Potier MC, Dubois B, Neri C, HampelH; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).
Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18.

4. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid – method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops EVanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.
J Neurochem. 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.

5. Pre-analytical stability of novel cerebrospinal fluid biomarkers.

Willemse EAJ, Vermeiren Y, Garcia-Ayllon MS, Bridel C, De Deyn PP, Engelborghs S, van der Flier WM, Jansen EEW, Lopez-Font IB, Mendes V, Manadas B, de Roeck N, Saez-Valero J, Struys EA, Vanmechelen E, Andreasson U, Teunissen CE.
Clin Chim Acta. 2019 Oct;497:204-211. doi: 10.1016/j.cca.2019.07.024. Epub 2019 Jul 23.

6. Parkinson’s disease biomarkers based on α-Synuclein.

Muneera Fayyad, Safa Salim,  Nour Majbour, Daniel Erskine, Erik Stoops, Brit Mollenhauer, Omar M. A. El‐Agnaf.
J Neurochem. 2019 Sep;150(5):626-636. doi: 10.1111/jnc.14809. Epub 2019 Jul 28.

7. CERTIFICATION REPORT: The certification of Amyloid β1-42 in CSF in ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC.

Julia Kuhlmann, Sébastien Boulo, Ulf Andreasson, Maria Bjerke, Josef Pannee, Jean Charoud-Got, Guy Auclair, Stéphane Mazoua, Stefanie Trapmann, Heinz Schimmel, Hendrik Emons, Doris Florian, Milena Quaglia, Erik Portelius, Magdalena Korecka, Leslie M. Shaw, Mary Lame, Erin Chambers, Hugo Vanderstichele, Erik Stoops, Andreas Leinenbach, Tobias Bittner, Rand G. Jenkins, Vesna Kostanjavecki, Piotr Lewczuk, Henrik Zetterberg, Ingrid Zegers, Kaj Blennow.
Publications Office of the European Union, Luxembourg, 2017, 978-92-79-70556-4, doi:10.2760/621427, JRC107381.

8. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.

Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, Vanderstichele H, Demeyer L, Stoops E, Trojanowski JQ, Lee VM, Zerr I.
Mol Neurobiol. 2019 May;56(5):3476-3483. doi: 10.1007/s12035-018-1313-4. Epub 2018 Aug 22.

9. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease.

Chatterjee P, Elmi M, Goozee K, Shah T, Sohrabi HR, Dias CB, Pedrini S, Shen K, Asih PR, Dave P, Taddei K, Vanderstichele H, Zetterberg H, Blennow K, Martins RN.
J Alzheimers Dis. 2019;71(3):775-783. doi: 10.3233/JAD-190533.

10. Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD.

Vergallo A, Houot M, Cavedo E, Lemercier P, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Lista S, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).
Alzheimers Dement. 2019 Oct;15(10):1274-1285. doi: 10.1016/j.jalz.2019.07.001.

11. APP-derived peptides reflect neurodegeneration in frontotemporal dementia.

Illán-Gala I, Pegueroles J, Montal V, Alcolea D, Vilaplana E, Bejanin A, Borrego-Écija S, Sampedro F, Subirana A, Sánchez-Saudinós MB, Rojas-García R, Vanderstichele H, Blesa R, Clarimón J, Antonell A, Lladó A, Sánchez-Valle R, Fortea J, Lleó A.
Ann Clin Transl Neurol. 2019 Dec;6(12):2518-2530. doi: 10.1002/acn3.50948. Epub 2019 Dec 2.

12. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer’s disease.

Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, Vanbrabant J, Jacobs D, Vanderstichele H, Vanmechelen E; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Worley P.
Alzheimers Dement (N Y). 2019 Dec 9;5:871-882. doi: 10.1016/j.trci.2019.11.002. eCollection 2019.